Premium
Bioactive glass and autogenous bone as bone graft substitutes in benign bone tumors
Author(s) -
Lindfors Nina C.,
Heikkilä Jouni T.,
Koski Ilona,
Mattila Kimmo,
Aho Allan J.
Publication year - 2009
Publication title -
journal of biomedical materials research part b: applied biomaterials
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.665
H-Index - 108
eISSN - 1552-4981
pISSN - 1552-4973
DOI - 10.1002/jbm.b.31263
Subject(s) - bioactive glass , medicine , nuclear medicine , dentistry , surgery
In a prospective randomized study, 25 patients with benign bone tumors were surgically treated with either bioactive glass S53P4 (BG) or autogenous bone (AB) as bone graft material. X‐rays were taken preoperatively and postoperatively at 2 weeks and at 3, 8, 12, 18, 24, and 36 months. In addition, for most of the patients, CT scans were performed at the same time‐points. No infections or material‐related adverse reactions occurred in any patient. The filled cavity was replaced faster by new bone in the AB group than in the BG group ( p = 0.0001). However, at 36 months, no statistical difference in cavity volume between the two groups was observed on X‐rays ( p = 0.7881) or on CT scans ( p = 0.9117). In the BG group at 3 years, the filled cavity appeared, however, dense on X‐rays, and glass granules on CT scans were observed. During the follow‐up period, the cortical thickness seemed to increase more in the BG group than in the AB group ( p < 0.0001). © 2008 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater, 2009